GILEAD SCIENCES, INC. Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0000882095

What is a 13F filing? Who files one and when · What 13F filings can't tell you

MidFocusedHealth TiltBuy & Hold how tags are computed

Q3 2026 · 5 positions · Total reported value $1.46B · Top-10 concentration 100.0% · Updated 2026-11-06

Last updated: 2026-11-06 · Source: SEC EDGAR Form 13F-HR

Turnover: 0.0% · 0 new · 0 cut · 0 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

In its Q3 2026 13F filing, GILEAD SCIENCES, INC. disclosed 5 equity positions with a combined reported value of $1.46B. The filing implies a focused portfolio: its ten largest positions account for 100.0% of reported value. HoldingsHub classifies the profile as Mid / Focused / Health Tilt / Buy & Hold.

The largest disclosed positions as of Q3 2026 were RCUS ($811.70M), LKFT ($501.28M), ASMB ($116.91M). By sector, the heaviest allocations are Health Care 65.8%, Other 34.2%. Versus the prior quarter, allocation shifted toward Other (+3.9pp) and away from Health Care (-3.9pp).

Versus the prior quarter, GILEAD SCIENCES, INC. opened 0 new positions, trimmed 0 and fully exited 0, a turnover rate of 0.0% of positions. The portfolio's overlap with the prior quarter was 100% of names.

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

Insider Transactions (Form 4)

Latest GILEAD SCIENCES, INC. buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

Transaction date Activity Security Shares Price Filing
2026-05-26 Award ASSEMBLY BIOSCIENCES, INC. 471,698 $26.50 SEC filing

All insider transactions →

Fund Profile

Gilead Sciences files quarterly US equity holdings with the SEC on Form 13F. Its latest filing (Q2 2026) lists 5 positions worth $1.65B in total. HoldingsHub carries 7 quarters of its filings (Q4 2024–Q2 2026).

Portfolio Structure

  • 5 positions · $1.65B reported value (Q2 2026)
  • Top 10 holdings = 100.0% of reported value
  • Largest position: RCUS (ARCUS BIOSCIENCES INC) at 58.8%
  • Average position size: $329.75M

Sector Tilt

  • Health Care 69.7%
  • (classified holdings cover 70% of value)

Quarterly Activity

  • Q2 2026: 1 added, 1 exited
  • 4 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

AI Rebalance Analysis

1. Overall Direction and Market View: Gilead Sciences' rebalancing in Q2 2026 appears to be conservative, with a focus on maintaining existing positions rather than making significant changes. The fund's top holdings remain largely the same, suggesting a neutral to slightly bullish market view with an emphasis on stability. 2. Key Moves: - Added: Assembly Biosciences (ASMB) with a 10.5% increase in share count, indicating a new addition or a significant boost in confidence in the company. - No Changes: Shares in Arcus Biosciences (RCUS), Lakefront Biotherapeutics (LKFT), Kymera Therapeutics (KYTX), and Xilio Therapeutics (XLO) remained unchanged in terms of share count and action, signifying a hold strategy. 3. Portfolio Structure: - Passive vs. Active: The portfolio appears to be more passive in nature, with a focus on maintaining existing positions rather than actively seeking out new opportunities. - Sector Bias: A clear bias towards the healthcare sector, as evidenced by the presence of several healthcare-related companies. - Risk Appetite: The risk appetite seems moderate, with a preference for stability and existing investments rather than venturing into higher-risk assets. 4. Per-Holding One-Liner: - RCUS (Arcus Biosciences Inc.): A clinical-stage biotechnology company focused on developing novel cancer immunotherapies. 'Unverified' - LKFT (Lakefront Biotherapeutics NV): A biotechnology company focused on the development of therapies for rare genetic diseases. 'Unverified' - ASMB (Assembly Biosciences Inc.): A clinical-stage biotechnology company developing therapies for liver disease and other indications. 'Unverified' - KYTX (Kymera Therapeutics Inc.): A clinical-stage biotechnology company developing novel therapies for autoimmune and orphan diseases. 'Unverified' - XLO (Xilio Therapeutics Inc.): A clinical-stage biotechnology company focused on developing treatments for liver and metabolic diseases. 'Unverified' 5. One-Sentence Style Summary: Gilead Sciences maintained a conservative and stable portfolio approach in Q2 2026, with a focus on existing healthcare investments and a slight increase in exposure to Assembly Biosciences.

Generated by GLM-4.5-flash from the latest 13F holdings and quarter-over-quarter changes. For reference only, not investment advice.

Sector Allocation

Health Care 65.8%
Other 34.2%
Sort by: Value Shares Weight Sector Change · CSV
# Shares Value Weight Allocation Change
1 31.42M $811.70M 55.45%
55.45%
Hold
2 16.71M $501.28M 34.24%
34.24%
Hold
3 4.98M $116.91M 7.99%
7.99%
Hold
4 4.13M $28.06M 1.92%
1.92%
Hold
5 650.39K $5.89M 0.40%
0.40%
Hold

FAQ

What did GILEAD SCIENCES, INC. buy in 2026-Q3?

In its 2026-Q3 13F filing, GILEAD SCIENCES, INC. reported 5 equity positions worth $1.46B in aggregate; its largest disclosed positions were RCUS ($811.70M), LKFT ($501.28M), ASMB ($116.91M).

How large is GILEAD SCIENCES, INC.'s portfolio?

GILEAD SCIENCES, INC. reported $1.46B of long equity holdings across 5 positions as of 2026-Q3. Top-10 holdings account for 100.0% of reported value.

What is GILEAD SCIENCES, INC.'s investment style?

HoldingsHub classifies the portfolio as Mid / Focused / Health Tilt / Buy & Hold, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/gilead-sciences/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →